

1                   **The Pivotal Role of 99mTc-MDP Bone Scintigraphy in Detecting**  
2                   **Widespread Extra-Osseous Metastases in Osteogenic Osteosarcoma: A**  
3                   **Case Report and Literature Review**

4

5

6                   **Abstract**

7                   **Background:** Osteogenic osteosarcoma is a highly aggressive primary malignant bone tumor  
8                   with a pronounced propensity for early hematogenous metastasis. While 99mTc-Methylene  
9                   Diphosphonate (99mTc-MDP) bone scintigraphy is a cornerstone for detecting skeletal  
10                  metastases, its exceptional utility in identifying metabolically active extra-osseous metastases,  
11                  a hallmark of osteosarcoma's osteogenic potential, is a critical but less emphasized  
12                  application.

13                  **Case Presentation:** We report a compelling case of a 29-year-old male with a history of  
14                  osteogenic osteosarcoma of the right humerus, initially metastatic to the lungs, treated with  
15                  radical surgery and adjuvant chemotherapy. A routine follow-up 99mTc-MDP bone  
16                  scintigraphy revealed not only a focal intense uptake at the right shoulder amputation stump,  
17                  indicative of local recurrence, but also revealed multiple, unexpected sites of intense extra-  
18                  skeletal radiotracer uptake. These were localized to the thorax, left lateral chest wall, right  
19                  iliac fossa, and right thigh. Subsequent diagnostic contrast-enhanced computed tomography  
20                  (CT) of the chest, abdomen, and pelvis confirmed extensive secondary involvement, including  
21                  pulmonary, peritoneal, nodal, muscular, and subcutaneous metastases, demonstrating  
22                  excellent spatial correlation with the scintigraphic findings.

23                  **Conclusion:** This case underscores the high metastatic potential of osteogenic osteosarcoma,  
24                  extending beyond bone to soft tissues and viscera. It powerfully illustrates that 99mTc-MDP  
25                  bone scintigraphy serves as a highly sensitive initial screening tool for detecting both osseous  
26                  and extra-osseous metastatic disease due to the osteoid-producing nature of these metastases.  
27                  We further discuss the diagnostic implications and advocate for the integrated use of hybrid  
28                  imaging, specifically Single-Photon Emission Computed Tomography/Computed  
29                  Tomography (SPECT/CT), to enhance anatomical localization and diagnostic specificity,  
30                  thereby refining staging accuracy and guiding optimal therapeutic strategies.

31 **Keywords:** Osteogenic Osteosarcoma; Extra-Osseous Metastases;  $^{99m}\text{Tc}$ -MDP Bone  
32 Scintigraphy; SPECT/CT; Soft Tissue Metastases; Case Report.

33

34

## 35 **Introduction**

36 Osteogenic osteosarcoma (OS) is the most common primary malignant bone tumor in children  
37 and adolescents, characterized by the direct formation of osteoid or immature bone by  
38 malignant proliferating spindle cells [1]. It exhibits aggressive biological behavior with a high  
39 propensity for hematogenous dissemination, most commonly to the lungs and other skeletal  
40 sites [2]. Accurate staging at diagnosis and during follow-up is paramount, as the presence  
41 and extent of metastases are the most critical prognostic factors and dictate treatment strategy  
42 [3].

43 Technetium-99m methylene diphosphonate ( $^{99m}\text{Tc}$ -MDP) bone scintigraphy is a  
44 fundamental nuclear medicine imaging modality in oncology. Its mechanism relies on the  
45 adsorption of the diphosphonate compound onto hydroxyapatite crystals in areas of increased  
46 osteoblastic activity and blood flow [4]. While its primary application in OS is the detection  
47 of skeletal metastases (bone-to-bone spread) and assessment of the primary tumor's metabolic  
48 activity, it possesses a unique capability to visualize extra-osseous (soft tissue and visceral)  
49 metastases. This occurs when these metastases retain the tumor's inherent osteogenic  
50 potential, producing microcalcifications or osteoid that avidly bind the radiopharmaceutical  
51 [5, 6].

52 We present a compelling case of a young adult with osteogenic OS that illustrates the  
53 exceptional sensitivity of planar  $^{99m}\text{Tc}$ -MDP bone scintigraphy in uncovering widespread,  
54 metabolically active extra-osseous metastatic disease. This case highlights the technique's  
55 value as a whole-body screening tool and serves as a springboard to discuss the  
56 complementary role of advanced hybrid imaging like Single-Photon Emission Computed  
57 Tomography/Computed Tomography (SPECT/CT) in refining diagnosis.

58 **Case Presentation**

59 A 29-year-old male with no significant past medical history presented with a several-month  
60 history of progressive pain and swelling in his right proximal humerus. Initial radiographs and  
61 subsequent magnetic resonance imaging (MRI) revealed a large, aggressive, osteolytic and  
62 osteoblastic lesion involving the metaphysis and diaphysis of the right humerus, with a  
63 substantial soft tissue component. A core needle biopsy confirmed the diagnosis of high-grade  
64 conventional osteogenic osteosarcoma. Staging computed tomography (CT) of the chest at the  
65 time of diagnosis revealed multiple bilateral pulmonary nodules, consistent with synchronous  
66 metastatic disease (Stage IV).

67 The patient underwent a multidisciplinary evaluation and commenced neoadjuvant  
68 chemotherapy according to a standard OS protocol (based on regimens containing high-dose  
69 methotrexate, doxorubicin, and cisplatin). Following three cycles, he underwent a radical  
70 resection of the right humerus with a wide surgical margin, performed via a forequarter  
71 amputation (interscapulothoracic amputation). Histopathological examination of the surgical  
72 specimen confirmed the diagnosis and showed a poor histologic response to chemotherapy  
73 (>90% viable tumor cells). The patient subsequently completed his adjuvant chemotherapy  
74 course.

75 Six months after completing adjuvant therapy, during routine surveillance, the patient  
76 remained asymptomatic. However, a follow-up whole-body  $^{99m}\text{Tc}$ -MDP planar bone  
77 scintigraphy was performed. The study revealed two critical findings: an intense, focal area of  
78 increased radiotracer uptake at the surgical site of the right shoulder/amputation stump, highly  
79 suggestive of local tumor recurrence, and multiple unexpected, and intensely hypermetabolic  
80 foci clearly located outside the skeletal system. These included foci in the mid-thorax, the soft  
81 tissues of the left lateral chest wall, the right iliac fossa region, and the proximal right thigh  
82 (Figure 1).

83 To further characterize these alarming extra-skeletal findings, a diagnostic contrast-enhanced  
84 CT scan of the chest, abdomen, and pelvis was urgently obtained. The CT scan confirmed  
85 extensive metastatic progression. It identified an increase in size and number of bilateral  
86 pulmonary nodules, and multiple discrete metastatic deposits within various muscle groups  
87 (e.g., intercostal, iliopsoas, thigh musculature) and subcutaneous tissues.

88 Retrospective side-by-side analysis demonstrated an excellent spatial correlation between the  
89 intense uptake foci on the planar bone scan and the corresponding soft tissue/visceral lesions  
90 identified on CT (Figure 2). This confirmed that the scintigraphic findings represented  
91 widespread extra-osseous metastatic disease from osteogenic OS.

92 Given the disseminated nature of the disease, the patient was presented again to the  
93 multidisciplinary tumor board. Further curative-intent surgery was not feasible. The decision  
94 was made to initiate second-line systemic therapy.

## 95 **Discussion**

96 This case eloquently demonstrates several key principles in the management and imaging of  
97 osteogenic osteosarcoma. First, it underscores the tumor's aggressive and unpredictable  
98 biology, with progression occurring despite aggressive multimodal primary therapy. Second,  
99 and most centrally, it highlights the indispensable role of  $99m\text{Tc}$ -MDP bone scintigraphy as a  
100 sensitive, whole-body survey tool capable of detecting both skeletal *and* extra-skeletal  
101 metastases.

102 The pathophysiological basis for this lies in the fundamental nature of osteogenic OS. The  
103 malignant cells produce osteoid, even at metastatic sites. This ectopic osteoid formation,  
104 along with associated microcalcifications and increased vascularity, creates a nidus for  
105  $99m\text{Tc}$ -MDP adsorption [5, 6]. Consequently, metabolically active extra-osseous metastases  
106 can manifest with an intensity equal to or greater than that of normal bone, making them  
107 conspicuous on planar imaging, as vividly shown in our patient.

108 The primary strength of planar bone scintigraphy in this context is its high sensitivity and  
109 ability to screen the entire body efficiently and cost-effectively. It can identify unsuspected  
110 sites of disease that might be outside the field of view of a routine CT scan, potentially  
111 altering disease stage and management, as it did here [7].

112 However, a significant limitation of planar imaging is its poor anatomical resolution. While it  
113 can confirm the *presence* and metabolic activity of a lesion, it cannot precisely *localize* it  
114 within soft tissue, distinguish subcutaneous from muscular involvement, or reliably  
115 differentiate metastatic uptake from other benign causes of soft tissue calcification (e.g.,

116 dystrophic calcification, myositis ossificans) [8]. This necessitated the follow-up CT scan in  
117 our case for definitive anatomical mapping.

118 This gap in diagnostic specificity is where hybrid imaging, particularly SPECT/CT, offers a  
119 transformative advantage. SPECT/CT seamlessly fuses the high functional sensitivity of  
120 scintigraphy with the detailed anatomical roadmap provided by CT in a single session [9]. In a  
121 case like ours, SPECT/CT would have likely provided immediate, precise localization of the  
122 extra-osseous foci, potentially characterizing them as muscular, nodal, or peritoneal without  
123 the need for a separate, delayed CT study. This integration reduces diagnostic uncertainty,  
124 minimizes the risk of false-positive interpretations, and accelerates clinical decision-making  
125 [10].

126 The detection of such widespread extra-osseous disease carries profound prognostic  
127 implications. It signifies a highly aggressive tumor phenotype and shifts the treatment  
128 paradigm from localized strategies (like surgery or radiation for oligometastases) to systemic  
129 therapy. Our case, therefore, reinforces that bone scintigraphy remains a crucial component of  
130 the surveillance arsenal for OS, not merely for bone but for comprehensive metastatic  
131 assessment.

## 132 Conclusion

133 This case report vividly illustrates the high metastatic potential of osteogenic osteosarcoma,  
134 which can involve diverse extra-osseous sites. Planar  $^{99m}\text{Tc}$ -MDP bone scintigraphy proved  
135 to be a critical and highly sensitive initial investigation, successfully detecting metabolically  
136 active soft tissue and visceral metastases due to their osteogenic nature, which would have  
137 otherwise been missed on a skeletal survey alone.

138 We emphasize that while planar scintigraphy is an excellent screening tool, the inherent lack  
139 of anatomical detail is a key limitation. Therefore, based on the learning points from this case,  
140 we advocate for the more integrated use of SPECT/CT in the follow-up of high-risk  
141 osteosarcoma patients. This advanced hybrid modality can provide a "one-stop-shop"  
142 evaluation, offering superior diagnostic accuracy by precisely correlating functional and  
143 anatomical information. This leads to more confident staging, better guidance for biopsy or  
144 treatment planning, and ultimately, optimized patient management.

145 **List of Abbreviations**

146 OS: Osteosarcoma  
147  $^{99m}\text{Tc}$ -MDP: Technetium-99m Methylene Diphosphonate  
148 SPECT/CT: Single-Photon Emission Computed Tomography/Computed Tomography  
149 CT: Computed Tomography  
150 MRI: Magnetic Resonance Imaging

151 **Declarations**

152 • **Ethics approval and consent to participate:** Written informed consent was obtained from  
153 the patient for publication of this case report and any accompanying images.  
154 • **Consent for publication:** Obtained from the patient (as above).  
155 • **Availability of data and materials:** The datasets used and/or analyzed during the current  
156 case are available from the corresponding author on reasonable request.  
157 • **Competing interests:** The authors declare that they have no competing interests.  
158 **Funding:** No specific funding was received for this case report.

159 **References**

160 [1] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973  
161 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer*.  
162 2009;115(7):1531-1543.  
163 [2] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade  
164 osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant  
165 cooperative osteosarcoma study group protocols. *J Clin Oncol*. 2002;20(3):776-790.  
166 [3] Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and  
167 outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group  
168 protocols. *J Clin Oncol*. 2003;21(10):2011-2018.  
169 [4] Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and  
170 hybrid modalities. *J Nucl Med*. 2005;46(8):1356-1367.  
171 [5] Feldman F, van Heertum R, Saxena C, et al. 18FDG-PET applications for cartilage  
172 neoplasms. *Skeletal Radiol*. 2005;34(7):367-374.  
173 [6] Van der Woude HJ, Bloem JL, Verstraete KL, et al. Osteosarcoma and Ewing's sarcoma  
174 after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor  
175 before surgery. *AJR Am J Roentgenol*. 1995;165(3):593-598.  
176 [7] Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous  
177 metastases from malignant primary bone tumours: comparison with bone scintigraphy. *Eur J*  
178 *Nucl Med*. 2000;27(9):1305-1311.  
179 [8] Strobel K, Exner UE, Stumpe KD, et al. The additional value of CT images interpretation  
180 in the differential diagnosis of benign vs. malignant primary bone lesions with  $^{99m}\text{Tc}$ -MDP  
181 SPECT. *Eur J Nucl Med Mol Imaging*. 2008;35(11):2000-2008.  
182 [9] Romer W, Nomayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased  
183 bone metabolism classified as indeterminate on SPECT in cancer patients. *J Nucl Med*.  
184 2006;47(7):1102-1106.  
185 [10] Hirschmann MT, Davda K, Rasch H, et al. Clinical value of combined single photon

186 emission computerized tomography and conventional computer tomography (SPECT/CT) in  
187 sports medicine. *Sports Med Arthrosc Rev*. 2016;24(1):4-9.

188

189

190

191

192

193

194


195

196

197


198 **Figures**

199



200

201 **Figure 1: Whole-body Tc-MDP bone scan showing pathological hypermetabolic foci in**  
202 **at the level of the right shoulder amputation stump and extra-osseous foci projecting to**  
203 **the thorax, soft tissues of the left lateral chest wall, right iliac fossa and right thigh**



204

205 **Figure 2:CT scan of the chest, abdomen, and pelvis with axial and coronal CT slices**  
206 **showing secondary pulmonary, lymph node, and subcostal lesions**